2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 29

BTK Inhibition Ameliorates Lupus-Associated Neuropsychiatric and Skin Disease
Abstract Number: 2561

BTK Inhibition Ameliorates Renal Disease in Spontaneous Murine Lupus Nephritis
Abstract Number: 1057

Budgetary Impact Analysis of Real-World Dosing Patterns in Matched Cohorts of Rheumatoid Arthritis Patients Treated with Infliximab or Golimumab Intravenous Anti-TNF Medications
Abstract Number: 3

Burden of Antiphospholipid Syndrome in a Thromboembolic Disease Registry
Abstract Number: 1033

Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity
Abstract Number: 1958

Burden of Rheumatic Disease Among Korean Women in Childbearing Years Based on the National Health Insurance Service-National Sample Cohort
Abstract Number: 2117

C-Reactive Protein and Serum Amyloid a in Sepsis, Acute Appendicitis and Familial Mediterranean Fever
Abstract Number: 1437

C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Abstract Number: 1635

Cachexia in Systemic Lupus Erythematosus- an Underrecognized Syndrome
Abstract Number: 1218

Caffeine Consumption and Risk of Osteoporosis: A Cross Sectional Study of 3, 210 Patients from the National Health and Nutrition Examination Survey
Abstract Number: 2086

Calcium Pyrophosphate Crystal Size, Shape and Appearance Variability
Abstract Number: 1396

Can 3 0-10 Physician Visual Analog Scales (VAS) to Assess Levels of Inflammation, Damage and Distress Offer Comprehensive Quantitative Data That May be As Informative As Detailed, Formal Swollen and Tender Joint Counts?
Abstract Number: 2244

Can Achieving Remission Improve Work Ability and Quality of Life in Early Rheumatoid Arthritis (RA) Patients? a Prospective Cohort Study
Abstract Number: 1903

Can Achieving Sustained DAS Remission Prevent Arterial Stiffness Progression in Early Rheumatoid Arthritis – a Post-Hoc Analysis of a Randomized Controlled Study
Abstract Number: 2545

Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Two-Year Prospective Cohort Study in Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].